|
VS-7375 Clinical Trials
3 actively recruiting trials across 1 location
▲ +2 trials since June 2026
Pipeline
Phase 2: 2Phase 1/2: 1
Top Sponsors
- Verastem, Inc.3
Indications
- Cancer3
- G12D Mutated KRAS2
- Colorectal Cancer2
- Pancreatic Ductal Adenocarcinoma (PDAC)1
- Pancreatic Ductal Adenocarcinoma1
Los Angeles, California3 trials
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Cedars-Sinai Medical Center
Phase 1/2
Phase 2
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.